Literature DB >> 12431993

Transcription dependence of chromosomal gene targeting by triplex-forming oligonucleotides.

Margaret A Macris1, Peter M Glazer.   

Abstract

Triplex-forming oligonucleotides (TFOs) recognize and bind to specific DNA sequences and have been used to modify gene function in cells. To study factors that might influence triplex formation at chromosomal sites in mammalian cells, we developed a restriction protection assay to detect triplex-directed psoralen crosslinks in genomic DNA prepared from TFO-transfected cells. Using this assay, we detected binding of a G-rich TFO to a chromosomal site even in the absence of transcription when high concentrations of the TFO were used for transfection. However, experimental induction of transcription at the target site, via an ecdysone-responsive promoter, resulted in substantial increases (3-fold or more) in target site crosslinking, especially at low TFO concentrations. When RNA polymerase activity was inhibited, even in the ecdysone-induced cells, the level of TFO binding was significantly decreased, indicating that transcription through the target region, and not just transcription factor binding, is necessary for the enhanced chromosomal targeting by TFOs. These findings provide evidence that physiologic activity at a chromosomal target site can influence its accessibility to TFOs and suggest that gene targeting by small molecules may be most effective at highly expressed chromosomal loci.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12431993     DOI: 10.1074/jbc.M206542200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities.

Authors:  Taco G Uil; Hidde J Haisma; Marianne G Rots
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

2.  Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins.

Authors:  Kahina Oussedik; Jean-Christophe François; Ludovic Halby; Catherine Senamaud-Beaufort; Géraldine Toutirais; Sabrina Dallavalle; Yves Pommier; Claudio Pisano; Paola B Arimondo
Journal:  FASEB J       Date:  2010-02-23       Impact factor: 5.191

3.  Chromosomal position effects on AAV-mediated gene targeting.

Authors:  Anda M Cornea; David W Russell
Journal:  Nucleic Acids Res       Date:  2010-02-25       Impact factor: 16.971

Review 4.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

5.  Sequence-specific triple helix formation with genomic DNA.

Authors:  Zhaoyang Ye; Ramareddy V Guntaka; Ram I Mahato
Journal:  Biochemistry       Date:  2007-09-11       Impact factor: 3.162

6.  Local delivery of gene-modifying triplex-forming molecules to the epidermis.

Authors:  Faye A Rogers; Rong-Hua Hu; Leonard M Milstone
Journal:  J Invest Dermatol       Date:  2012-09-27       Impact factor: 8.551

7.  Targeting chromosomal sites with locked nucleic acid-modified triplex-forming oligonucleotides: study of efficiency dependence on DNA nuclear environment.

Authors:  Erika Brunet; Maddalena Corgnali; Fabio Cannata; Loïc Perrouault; Carine Giovannangeli
Journal:  Nucleic Acids Res       Date:  2006-09-01       Impact factor: 16.971

Review 8.  The triple helix: 50 years later, the outcome.

Authors:  Maria Duca; Pierre Vekhoff; Kahina Oussedik; Ludovic Halby; Paola B Arimondo
Journal:  Nucleic Acids Res       Date:  2008-08-01       Impact factor: 16.971

9.  Site-directed gene mutation at mixed sequence targets by psoralen-conjugated pseudo-complementary peptide nucleic acids.

Authors:  Ki-Hyun Kim; Peter E Nielsen; Peter M Glazer
Journal:  Nucleic Acids Res       Date:  2007-10-30       Impact factor: 16.971

10.  XPD-dependent activation of apoptosis in response to triplex-induced DNA damage.

Authors:  Meetu Kaushik Tiwari; Faye A Rogers
Journal:  Nucleic Acids Res       Date:  2013-08-02       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.